Cinnarizine‐induced parkinsonism: Ten years later
Identifieur interne : 003125 ( Istex/Corpus ); précédent : 003124; suivant : 003126Cinnarizine‐induced parkinsonism: Ten years later
Auteurs : José F. Martí-Mass ; Juan J. PozaSource :
- Movement Disorders [ 0885-3185 ] ; 1998-05.
English descriptors
Abstract
A retrospective study was carried out to investigate the evolution of patients diagnosed with cinnarizineinduced parkinsonism (CIP) over the past 15 years. A total of 74 cases of CIP were found among 172 patients with druginduced parkinsonism (DIP). Both CIP and other DIP were significantly more frequent in women. No clinical differences between CIP and other DIP were found. Most of the patients (66 of 74) completely recovered after cinnarizine withdrawal in 1–16 months. Eleven patients later developed Parkinson's disease; four of them had previously recovered. Five patients had tardive dyskinesia. CIP accounts for a high proportion of DIP referred to neurologists in populations in which cinnarizine is widely prescribed. The symptoms typically resolve after drug withdrawal, although complete recovery may take more than 1 year.
Url:
DOI: 10.1002/mds.870130313
Links to Exploration step
ISTEX:6981C4AAD30D55CD0028FF565215A1BB45A14F0ALe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cinnarizine‐induced parkinsonism: Ten years later</title><author><name sortKey="Marti Ass, Jose F" sort="Marti Ass, Jose F" uniqKey="Marti Ass J" first="José F." last="Martí-Mass">José F. Martí-Mass</name><affiliation><mods:affiliation>Department of Neurology, Hospital Ntra. Sra. Aránzazu, San Sebastián, Basque Country, Spain</mods:affiliation></affiliation></author><author><name sortKey="Poza, Juan J" sort="Poza, Juan J" uniqKey="Poza J" first="Juan J." last="Poza">Juan J. Poza</name><affiliation><mods:affiliation>Department of Neurology, Hospital Ntra. Sra. Aránzazu, San Sebastián, Basque Country, Spain</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:6981C4AAD30D55CD0028FF565215A1BB45A14F0A</idno><date when="1998" year="1998">1998</date><idno type="doi">10.1002/mds.870130313</idno><idno type="url">https://api.istex.fr/document/6981C4AAD30D55CD0028FF565215A1BB45A14F0A/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">003125</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Cinnarizine‐induced parkinsonism: Ten years later</title><author><name sortKey="Marti Ass, Jose F" sort="Marti Ass, Jose F" uniqKey="Marti Ass J" first="José F." last="Martí-Mass">José F. Martí-Mass</name><affiliation><mods:affiliation>Department of Neurology, Hospital Ntra. Sra. Aránzazu, San Sebastián, Basque Country, Spain</mods:affiliation></affiliation></author><author><name sortKey="Poza, Juan J" sort="Poza, Juan J" uniqKey="Poza J" first="Juan J." last="Poza">Juan J. Poza</name><affiliation><mods:affiliation>Department of Neurology, Hospital Ntra. Sra. Aránzazu, San Sebastián, Basque Country, Spain</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1998-05">1998-05</date><biblScope unit="vol">13</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="453">453</biblScope><biblScope unit="page" to="456">456</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">6981C4AAD30D55CD0028FF565215A1BB45A14F0A</idno><idno type="DOI">10.1002/mds.870130313</idno><idno type="ArticleID">MDS870130313</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cinnarizine</term><term>Clinical characteristics</term><term>Drug‐induced parkinsonism</term><term>Evolution</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A retrospective study was carried out to investigate the evolution of patients diagnosed with cinnarizineinduced parkinsonism (CIP) over the past 15 years. A total of 74 cases of CIP were found among 172 patients with druginduced parkinsonism (DIP). Both CIP and other DIP were significantly more frequent in women. No clinical differences between CIP and other DIP were found. Most of the patients (66 of 74) completely recovered after cinnarizine withdrawal in 1–16 months. Eleven patients later developed Parkinson's disease; four of them had previously recovered. Five patients had tardive dyskinesia. CIP accounts for a high proportion of DIP referred to neurologists in populations in which cinnarizine is widely prescribed. The symptoms typically resolve after drug withdrawal, although complete recovery may take more than 1 year.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>José F. Martí‐Massó MD, PhD</name><affiliations><json:string>Department of Neurology, Hospital Ntra. Sra. Aránzazu, San Sebastián, Basque Country, Spain</json:string></affiliations></json:item><json:item><name>Juan J. Poza MD, PhD</name><affiliations><json:string>Department of Neurology, Hospital Ntra. Sra. Aránzazu, San Sebastián, Basque Country, Spain</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Drug‐induced parkinsonism</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Cinnarizine</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Clinical characteristics</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Evolution</value></json:item></subject><language><json:string>eng</json:string></language><abstract>A retrospective study was carried out to investigate the evolution of patients diagnosed with cinnarizineinduced parkinsonism (CIP) over the past 15 years. A total of 74 cases of CIP were found among 172 patients with druginduced parkinsonism (DIP). Both CIP and other DIP were significantly more frequent in women. No clinical differences between CIP and other DIP were found. Most of the patients (66 of 74) completely recovered after cinnarizine withdrawal in 1–16 months. Eleven patients later developed Parkinson's disease; four of them had previously recovered. Five patients had tardive dyskinesia. CIP accounts for a high proportion of DIP referred to neurologists in populations in which cinnarizine is widely prescribed. The symptoms typically resolve after drug withdrawal, although complete recovery may take more than 1 year.</abstract><qualityIndicators><score>3.786</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 792 pts (letter)</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>838</abstractCharCount><pdfWordCount>2274</pdfWordCount><pdfCharCount>14721</pdfCharCount><pdfPageCount>4</pdfPageCount><abstractWordCount>126</abstractWordCount></qualityIndicators><title>Cinnarizine‐induced parkinsonism: Ten years later</title><genre><json:string>Serial article</json:string></genre><host><volume>13</volume><pages><total>4</total><last>456</last><first>453</first></pages><issn><json:string>0885-3185</json:string></issn><issue>3</issue><subject><json:item><value>Article</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>1998</publicationDate><copyrightDate>1998</copyrightDate><doi><json:string>10.1002/mds.870130313</json:string></doi><id>6981C4AAD30D55CD0028FF565215A1BB45A14F0A</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/6981C4AAD30D55CD0028FF565215A1BB45A14F0A/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/6981C4AAD30D55CD0028FF565215A1BB45A14F0A/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/6981C4AAD30D55CD0028FF565215A1BB45A14F0A/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Cinnarizine‐induced parkinsonism: Ten years later</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>1998</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Cinnarizine‐induced parkinsonism: Ten years later</title><author><persName><forename type="first">José F.</forename><surname>Martí‐Massó</surname><roleName type="degree">MD, PhD</roleName></persName><note type="correspondence"><p>Correspondence: Travesía del Helecho 3° Izda, 20009 San Sebastián, Spain===</p></note><affiliation>Department of Neurology, Hospital Ntra. Sra. Aránzazu, San Sebastián, Basque Country, Spain</affiliation></author><author><persName><forename type="first">Juan J.</forename><surname>Poza</surname><roleName type="degree">MD, PhD</roleName></persName><affiliation>Department of Neurology, Hospital Ntra. Sra. Aránzazu, San Sebastián, Basque Country, Spain</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1998-05"></date><biblScope unit="vol">13</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="453">453</biblScope><biblScope unit="page" to="456">456</biblScope></imprint></monogr><idno type="istex">6981C4AAD30D55CD0028FF565215A1BB45A14F0A</idno><idno type="DOI">10.1002/mds.870130313</idno><idno type="ArticleID">MDS870130313</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1998</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>A retrospective study was carried out to investigate the evolution of patients diagnosed with cinnarizineinduced parkinsonism (CIP) over the past 15 years. A total of 74 cases of CIP were found among 172 patients with druginduced parkinsonism (DIP). Both CIP and other DIP were significantly more frequent in women. No clinical differences between CIP and other DIP were found. Most of the patients (66 of 74) completely recovered after cinnarizine withdrawal in 1–16 months. Eleven patients later developed Parkinson's disease; four of them had previously recovered. Five patients had tardive dyskinesia. CIP accounts for a high proportion of DIP referred to neurologists in populations in which cinnarizine is widely prescribed. The symptoms typically resolve after drug withdrawal, although complete recovery may take more than 1 year.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Drug‐induced parkinsonism</term></item><item><term>Cinnarizine</term></item><item><term>Clinical characteristics</term></item><item><term>Evolution</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1997-03-17">Received</change><change when="1998-01-13">Registration</change><change when="1998-05">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/6981C4AAD30D55CD0028FF565215A1BB45A14F0A/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="tocForm">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="30"><doi origin="wiley" registered="yes">10.1002/mds.v13:3</doi><numberingGroup><numbering type="journalVolume" number="13">13</numbering><numbering type="journalIssue">3</numbering></numberingGroup><coverDate startDate="1998-05">May 1998</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="13" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.870130313</doi><idGroup><id type="unit" value="MDS870130313"></id></idGroup><countGroup><count type="pageTotal" number="4"></count></countGroup><titleGroup><title type="articleCategory">Article</title><title type="tocHeading1">Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 1998 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="1997-03-17"></event><event type="manuscriptRevised" date="1997-12-22"></event><event type="manuscriptAccepted" date="1998-01-13"></event><event type="firstOnline" date="2004-11-04"></event><event type="publishedOnlineFinalForm" date="2004-11-04"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:3.3.2 mode:FullText" date="2014-06-23"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.3.2 mode:FullText" date="2014-06-23"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">453</numbering><numbering type="pageLast">456</numbering></numberingGroup><correspondenceTo>Travesía del Helecho 3° Izda, 20009 San Sebastián, Spain===</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS870130313.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="3"></count><count type="referenceTotal" number="18"></count></countGroup><titleGroup><title type="main" xml:lang="en">Cinnarizine‐induced parkinsonism: Ten years later</title><title type="short" xml:lang="en">CINNARIZINE‐INDUCED PARKINSONISM</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>José F.</givenNames><familyName>Martí‐Massó</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Juan J.</givenNames><familyName>Poza</familyName><degrees>MD, PhD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="ES" type="organization"><unparsedAffiliation>Department of Neurology, Hospital Ntra. Sra. Aránzazu, San Sebastián, Basque Country, Spain</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Drug‐induced parkinsonism</keyword><keyword xml:id="kwd2">Cinnarizine</keyword><keyword xml:id="kwd3">Clinical characteristics</keyword><keyword xml:id="kwd4">Evolution</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>A retrospective study was carried out to investigate the evolution of patients diagnosed with cinnarizineinduced parkinsonism (CIP) over the past 15 years. A total of 74 cases of CIP were found among 172 patients with druginduced parkinsonism (DIP). Both CIP and other DIP were significantly more frequent in women. No clinical differences between CIP and other DIP were found. Most of the patients (66 of 74) completely recovered after cinnarizine withdrawal in 1–16 months. Eleven patients later developed Parkinson's disease; four of them had previously recovered. Five patients had tardive dyskinesia. CIP accounts for a high proportion of DIP referred to neurologists in populations in which cinnarizine is widely prescribed. The symptoms typically resolve after drug withdrawal, although complete recovery may take more than 1 year.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 3-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Cinnarizine‐induced parkinsonism: Ten years later</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>CINNARIZINE‐INDUCED PARKINSONISM</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Cinnarizine‐induced parkinsonism: Ten years later</title></titleInfo><name type="personal"><namePart type="given">José F.</namePart><namePart type="family">Martí‐Massó</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Neurology, Hospital Ntra. Sra. Aránzazu, San Sebastián, Basque Country, Spain</affiliation><description>Correspondence: Travesía del Helecho 3° Izda, 20009 San Sebastián, Spain===</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Juan J.</namePart><namePart type="family">Poza</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Neurology, Hospital Ntra. Sra. Aránzazu, San Sebastián, Basque Country, Spain</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">1998-05</dateIssued><dateCaptured encoding="w3cdtf">1997-03-17</dateCaptured><dateValid encoding="w3cdtf">1998-01-13</dateValid><copyrightDate encoding="w3cdtf">1998</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">3</extent><extent unit="references">18</extent></physicalDescription><abstract lang="en">A retrospective study was carried out to investigate the evolution of patients diagnosed with cinnarizineinduced parkinsonism (CIP) over the past 15 years. A total of 74 cases of CIP were found among 172 patients with druginduced parkinsonism (DIP). Both CIP and other DIP were significantly more frequent in women. No clinical differences between CIP and other DIP were found. Most of the patients (66 of 74) completely recovered after cinnarizine withdrawal in 1–16 months. Eleven patients later developed Parkinson's disease; four of them had previously recovered. Five patients had tardive dyskinesia. CIP accounts for a high proportion of DIP referred to neurologists in populations in which cinnarizine is widely prescribed. The symptoms typically resolve after drug withdrawal, although complete recovery may take more than 1 year.</abstract><subject lang="en"><genre>Keywords</genre><topic>Drug‐induced parkinsonism</topic><topic>Cinnarizine</topic><topic>Clinical characteristics</topic><topic>Evolution</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><detail type="issue"><caption>no.</caption><number>3</number></detail><extent unit="pages"><start>453</start><end>456</end><total>4</total></extent></part></relatedItem><identifier type="istex">6981C4AAD30D55CD0028FF565215A1BB45A14F0A</identifier><identifier type="DOI">10.1002/mds.870130313</identifier><identifier type="ArticleID">MDS870130313</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 1998 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003125 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 003125 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:6981C4AAD30D55CD0028FF565215A1BB45A14F0A
|texte= Cinnarizine‐induced parkinsonism: Ten years later
}}
| This area was generated with Dilib version V0.6.23. |  |